Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAMP: ADG20 for treatment of mild or moderate ambulatory COVID-19 at high risk of progression
2020-006082-11Phase 2Terminated
- Sponsor
- Invivyd
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing ADG20 with Placebo (2 arms). Primary endpoint: COVID-19 related hospitalization or all-cause death through Day 29. Started May 2021; status: terminated.
02
Drugs
adintrevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-006082-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006082-11.